Literature DB >> 15199102

Tamoxifen: Dr. Jekyll and Mr. Hyde?

Daniel F Hayes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15199102     DOI： 10.1093/jnci/djh191

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  p66 Shc and tyrosine-phosphorylated Shc in primary breast tumors identify patients likely to relapse despite tamoxifen therapy.

Authors:  A Raymond Frackelton; Li Lu; Pamela A Davol; Robert Bagdasaryan; Laurie J Hafer; Dennis C Sgroi
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

2.  The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance.

Authors:  Zsuzsanna Suba
Journal:  Drug Des Devel Ther       Date:  2015-08-06       Impact factor: 4.162

3.  Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implications.

Authors:  Zsuzsanna Suba
Journal:  Onco Targets Ther       Date:  2014-01-23       Impact factor: 4.147

Review 4.  Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery.

Authors:  Zsuzsanna Suba
Journal:  Recent Pat Anticancer Drug Discov       Date:  2016       Impact factor: 4.169
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.